VXRT - アビラジェン・セラピュ―ティクス (Vaxart Inc.)


   Vaxart Stock: Awaiting Platform Validation for the Bull-Case to Kick In  2022/03/07 19:34:39 TipRanks

Vaxart (VXRT) shot to prominence in the early days of the pandemic, as one of the small vaccine makers taking the fight to Covid-19. But that was a while ago

   Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform  2022/02/26 08:24:19 Seeking Alpha
   Vaxart GAAP EPS of -$0.17 misses by $0.01, revenue of $0.07M misses by $0.11M  2022/02/24 22:30:34 Seeking Alpha
Vaxart press release (NASDAQ:VXRT): Q4 GAAP EPS of -$0.17 misses by $0.01.Revenue of $0.07M (-80.6% Y/Y) misses by $0.11M.
   Vaxart shares fall following data on COVID vaccine  2022/02/24 14:20:44 Seeking Alpha
Shares of Vaxart (VXRT) are down 10% in premarket trading after releasing mid-stage data on its oral COVID-19 vaccine candidate.
   This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart  2022/02/17 15:07:07 Benzinga
Macy''s Inc (NYSE: M ) retail stores have something for everyone in the family, and over the past year, has returned unmistakable gains for bullish traders and investors. Since February 2021, Macy’s stock’s one-year return has outperformed several of the world’s most popular vaccine stocks: Moderna Inc (NASDAQ: MRNA ), Pfizer Inc. (NYSE: PFE ), BioNTech SE - ADR (NASDAQ: BNTX ), Novavax, Inc. (NASDAQ: … Full story available on Benzinga.com
   Vaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average of $7.62  2021/12/19 12:22:41 Dakota Financial News
Vaxart, Inc. (NASDAQ:VXRT)s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $7.62 and traded as low as $6.41. Vaxart shares last traded at $7.20, with a volume of 9,325,846 shares trading hands. A number of equities research analysts []
   Vaxart Stock Crosses 2 Key Levels Friday: What''s Next?  2021/12/17 19:42:52 Business Insider Markets
Vaxart Inc. (NASDAQ: VXRT ) shares were trading higher Friday after the company plans to test the cross-reactivity of its…
   Vaxart shares rise 8% on promise of oral COVID vaccine against Omicron  2021/12/17 19:27:11 Seeking Alpha
   A Sharp Uptick in Infections Reignites Fears of New Restrictions  2021/12/17 14:00:00 Benzinga
NEW YORK , Dec. 17, 2021 /PRNewswire/ -- The ongoing pandemic is causing renewed concerns as new variants are becoming more prominent. As an example, test positivity rates in New York City have doubled in just three days, Dr. Jay Varma , a top health advisor to Mayor Bill de Blasio , tweeted Thursday. According to data provided by the CDC on Wednesday, New York and New Jersey are the two states with the most rapid spread of the Omicron variant. To identify and track SARS-CoV-2 variants, CDC uses genomic surveillance. CDC''s national genomic surveillance system collects SARS-CoV-2 specimens for sequencing through the National SARS-CoV-2 Strain Surveillance (NS3) program, as well as SARS-CoV-2 sequences generated by commercial or academic laboratories contracted by CDC and state or local public health laboratories. In the meantime, restrictions for private businesses have become more strict. Todos Medical Ltd. (OTC: TOMDF ), Pfizer Inc. (NYSE: PFE ), Johnson & Johnson (NYSE: JNJ ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Vaxart, Inc. (NASDAQ: VXRT ) As a result of the most recent surge, schools like New York University and Cornell University have canceled in-person events and shifted finals online.
   Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron  2021/12/16 13:00:00 Intrado Digital Media
Cross-reactivity will be assessed using samples from Phase II clinical participants and in a parallel animal challenge study